Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
about
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerTargeted therapies and immunotherapy in non-small-cell lung cancerIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCAngiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).The distinctive nature of adenocarcinoma of the lungOptimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptorUpdate in Lung Cancer 2014Skin problems and EGFR-tyrosine kinase inhibitorUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsPhase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic CancerAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung CancerA phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis.A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumabThird-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerTriplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.The major thoracic vascular invasion of lung cancer.Combination therapy in combating cancer.Emerging treatment for advanced lung cancer with EGFR mutation.CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II studyDual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.Bevacizumab to combat EGFR-TKI resistance in a patient with advanced non-small cell lung cancer harboring an EGFR mutation: A case report.Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review.Targeting EGFR in lung cancer: Lessons learned and future perspectivesIntercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.Anti-VEGFR2 driven nuclear translocation of VEGFR2 and acquired malignant hallmarks are mutation dependent in glioblastoma.Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trialsSalvage treatment with apatinib for advanced non-small-cell lung cancer.
P2860
Q26471909-C3205DEE-EAC5-42B1-BDF4-C5EE4E347ECEQ26738986-517B7FB7-5CC4-429A-9A06-89C096F050BDQ26744339-FE5F9B7D-05F3-4AEA-8CEC-F7B4013F8E49Q26747276-8EC559FF-3F2B-47AB-AE77-BEDDB722ED2DQ26775394-A69031F4-FC33-4335-B65C-D1936F9B24DEQ26781159-1C05B18E-7A28-4EE8-A6C8-177726EEC165Q26859993-DD6027BD-5233-4810-9E51-B34646C189F7Q27027385-6111E62A-628F-4117-A536-E7D584FDAC24Q28069454-4E1C71AD-6F5A-4E18-9060-118680D92D0EQ28075291-07220A7D-6F34-4258-8CBB-754E83E53893Q28552089-EE8EB4D5-7310-4B16-8892-4BA2BBE108DCQ30399006-14687A43-5D45-442A-8659-D2BABA98713AQ33165980-E708ED3C-98F6-46C3-91E9-449A47EC6CC3Q33429242-8571D503-2D80-4CAA-A5F3-4CAECC2F2109Q33599860-FF13A00E-057F-4E8C-9A6A-429DC82530B9Q33662730-8DAF94C3-7A6D-4F9B-99C8-497757BA6E64Q33685254-6D1FD5DE-F560-4F1C-875C-7E695028D9EFQ33740707-A20F4F78-FDD8-49AB-9364-E093A7DD5F13Q33787355-CA3F7E30-18F0-4E8A-8B18-21DD9C61EEE7Q33835552-4E53973B-E093-4C4A-A555-43A0C8B6264AQ33914234-768F597B-8FB8-40C2-B26E-628336F8C983Q34483953-740634B7-A381-4511-87D3-3229E75AC9BDQ34581688-7736C799-66E8-494C-AC08-36055FD28659Q35545472-4C755604-EE1D-47E0-94C2-3E8D5892F917Q35790180-4A133F7F-118F-4594-9ABF-86740AA89D46Q35829916-5AF45F13-F0DC-4337-9CE9-8F3576528792Q36008274-0553A2A5-7326-477B-8F53-CFBA72B5D44DQ36824587-57F00454-02B3-4467-9415-08EBCB2838BAQ37001902-86745CCB-750D-4E61-9FE9-4ED57810C087Q37042424-FF104B98-89FB-4964-9495-09E6B2F3552BQ37258827-B141F1E8-2A0E-4F83-8A11-D1353073659FQ37357699-645111A5-3A2B-4834-AD02-0FFE51B78DD5Q37539775-E9217306-D912-4579-A87E-E3B486C26B4AQ37578362-97E2702C-ACAC-4CC2-A7BD-D21494FD0104Q37613594-BAB2391F-BEEF-4ACB-8124-44007AD717F8Q37639588-44701B47-2311-43CE-A47A-2DF50D5C2AD2Q37688567-E5FF17A9-510D-4334-BD1B-790C66D9311CQ37698613-12744F70-7400-4C7A-B7BA-8F5911D73533Q37701719-23D752AD-9754-4413-89D3-C93DFA656D61Q37725637-D53BAEE9-C406-4240-8D4A-5A8034566995
P2860
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Erlotinib alone or with bevaci ...... d, multicentre, phase 2 study.
@en
type
label
Erlotinib alone or with bevaci ...... d, multicentre, phase 2 study.
@en
prefLabel
Erlotinib alone or with bevaci ...... d, multicentre, phase 2 study.
@en
P2093
P1433
P1476
Erlotinib alone or with bevaci ...... d, multicentre, phase 2 study.
@en
P2093
Isamu Okamoto
Kazuhiko Nakagawa
Koichi Goto
Kosei Tajima
Makoto Maemondo
Makoto Nishio
Masahiro Fukuoka
Noboru Yamamoto
Nobuyuki Yamamoto
Ryosuke Harada
P304
P356
10.1016/S1470-2045(14)70381-X
P577
2014-08-27T00:00:00Z